Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, January 24, 2024; Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 23 January 2024, regarding the final results of the subsequent repair offering of shares in the Company (the "Subsequent Offering"). Inify Laboratories AB (publ.) announces that the below primary insiders were allocated new shares at the offer price in the Subsequent Offering as further specified in the attached PDMR notification forms: -          Monsun AS, a company closely associated with board member Magne Jordanger, has been allocated 2,034,376 shares in the Subsequent offering. Monsun AS will, subject to completion of the Subsequent Offering, own 8,043,896 shares in the Company. -          Martin Ingvar, member of the board, has been allocated 75,363shares in the Subsequent offering. Ingvar will, subject to the completion of the Subsequent Offering, own 176,563 shares in the Company. -          Fredrik Palm, CEO of Inify Laboratories, has been allocated 37,979 shares in the Subsequent Offering. Palm will, subject to the completion of the Subsequent Offering, own 91,049 shares in the Company. -          Ann-Charlotte Linderoth, CFO of Inify Laboratories, has been allocated 22,260 shares in the Subsequent Offering. Linderoth will, subject to the completion of the Subsequent Offering, own 73,000 shares in the Company. For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com (https://protect.checkpoint.com/v2/r02/___https://www.inify .com___.YzJlOnNjaGpkdGFzOmM6bzo0NDExNTA5OTM3OGNkZThmNzA1MWNiMjhhMDMxODI0OTo3OjM0O DE6MDM2ZGNhZmI0ZmNmMmZmNWI5OGU3Njc4NWE2NWQ4ODkwZmNhNmMwMDhhNWQ5ZjUwMGM5ODBmNDY5OD I1YzAyOTpwOkY6VA). This information is subject to the disclosure requirements in the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act. ### About Inify Laboratories Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer's organization. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.